BioCentury
ARTICLE | Company News

Bellicum pays Ariad for room to run

October 7, 2014 2:24 AM UTC

After raising $55 million in August, Bellicum Pharmaceuticals Inc. (Houston, Texas) on Monday committed to pay $50 million to Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) for exclusive worldwide rights to use the latter's cell-signaling technology in human cell therapies for all diseases on a royalty- and milestone-free basis.

Ariad also is returning its equity stake in Bellicum as part of the agreement, which restructures a 2006 deal for the second time. ...